557 related articles for article (PubMed ID: 22706887)
1. Adherence to antipsychotics and cardiometabolic medication: association with health care utilization and costs.
Hansen RA; Maciejewski M; Yu-Isenberg K; Farley JF
Psychiatr Serv; 2012 Sep; 63(9):920-8. PubMed ID: 22706887
[TBL] [Abstract][Full Text] [Related]
2. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia.
Gilmer TP; Dolder CR; Lacro JP; Folsom DP; Lindamer L; Garcia P; Jeste DV
Am J Psychiatry; 2004 Apr; 161(4):692-9. PubMed ID: 15056516
[TBL] [Abstract][Full Text] [Related]
3. Differential medication adherence among patients with schizophrenia and comorbid diabetes and hypertension.
Piette JD; Heisler M; Ganoczy D; McCarthy JF; Valenstein M
Psychiatr Serv; 2007 Feb; 58(2):207-12. PubMed ID: 17287377
[TBL] [Abstract][Full Text] [Related]
4. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia.
Offord S; Lin J; Mirski D; Wong B
Adv Ther; 2013 Mar; 30(3):286-97. PubMed ID: 23483449
[TBL] [Abstract][Full Text] [Related]
5. Antipsychotic adherence and its correlation to health outcomes for chronic comorbid conditions.
Farley JF; Hansen RA; Yu-Isenberg KS; Maciejewski ML
Prim Care Companion CNS Disord; 2012; 14(3):. PubMed ID: 23106028
[TBL] [Abstract][Full Text] [Related]
6. Adherence, health care utilization, and costs between long-acting injectable and oral antipsychotic medications in South Carolina Medicaid beneficiaries with schizophrenia.
Cai C; Kozma C; Patel C; Benson C; Yunusa I; Zhao P; Reeder G; Narasimhan M; Bank RL
J Manag Care Spec Pharm; 2024 Jun; 30(6):549-559. PubMed ID: 38824623
[TBL] [Abstract][Full Text] [Related]
7. Antipsychotic Medication Adherence and Diabetes-Related Hospitalizations Among Medicaid Recipients With Diabetes and Schizophrenia.
Egglefield K; Cogan L; Leckman-Westin E; Finnerty M
Psychiatr Serv; 2020 Mar; 71(3):236-242. PubMed ID: 31744428
[TBL] [Abstract][Full Text] [Related]
8. The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia.
Chen H; Kennedy WK; Dorfman JH; Fincham JE; Reeves J; Martin BC
Curr Med Res Opin; 2007 Jun; 23(6):1351-65. PubMed ID: 17559734
[TBL] [Abstract][Full Text] [Related]
9. One-Year Medication Treatment Patterns, Healthcare Resource Utilization, and Expenditures for Medicaid Patients with Schizophrenia Starting Oral Atypical Antipsychotic Medication.
Richards K; Johnsrud M; Zacker C; Sasané R
Adm Policy Ment Health; 2024 Mar; 51(2):207-216. PubMed ID: 38071724
[TBL] [Abstract][Full Text] [Related]
10. Impact of Medicaid prescription copayments on use of antipsychotics and other medications in patients with schizophrenia.
Doshi JA; Li P; Desai S; Marcus SC
J Med Econ; 2017 Dec; 20(12):1252-1260. PubMed ID: 28792299
[TBL] [Abstract][Full Text] [Related]
11. Effects of Medication Nonadherence and Comorbidity on Health Resource Utilization in Schizophrenia.
Desai R; Nayak R
J Manag Care Spec Pharm; 2019 Jan; 25(1):37-46. PubMed ID: 30589635
[TBL] [Abstract][Full Text] [Related]
12. Antipsychotic Adherence, Resource Use, and Costs Before and After the Initiation of Once-monthly Paliperidone Palmitate Therapy Among Medicaid Beneficiaries With Prior Schizophrenia Relapse.
Zhdanava M; Lin D; Lafeuille MH; Ghelerter I; Morrison L; Lefebvre P; Joshi K
Clin Ther; 2021 Mar; 43(3):535-548. PubMed ID: 33589216
[TBL] [Abstract][Full Text] [Related]
13. Outpatient antipsychotic treatment and inpatient costs of schizophrenia.
Marcus SC; Olfson M
Schizophr Bull; 2008 Jan; 34(1):173-80. PubMed ID: 17578893
[TBL] [Abstract][Full Text] [Related]
14. A comparison of treatment patterns, healthcare resource utilization, and costs among young adult Medicaid beneficiaries with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics in the US.
Manjelievskaia J; Amos TB; El Khoury AC; Vlahiotis A; Cole A; Juneau P
J Med Econ; 2018 Dec; 21(12):1221-1229. PubMed ID: 30238806
[TBL] [Abstract][Full Text] [Related]
15. Retrospective assessment of Medicaid step-therapy prior authorization policy for atypical antipsychotic medications.
Farley JF; Cline RR; Schommer JC; Hadsall RS; Nyman JA
Clin Ther; 2008 Aug; 30(8):1524-39; discussion 1506-7. PubMed ID: 18803994
[TBL] [Abstract][Full Text] [Related]
16. Effect of Medicaid Policy Changes on Medication Adherence: Differences by Baseline Adherence.
Amin K; Farley JF; Maciejewski ML; Domino ME
J Manag Care Spec Pharm; 2017 Mar; 23(3):337-345. PubMed ID: 28230447
[TBL] [Abstract][Full Text] [Related]
17. Differences in health services utilization and costs between antihypertensive medication users versus nonusers in adults with diabetes and concomitant hypertension from Medical Expenditure Panel Survey pooled years 2006 to 2009.
Davis-Ajami ML; Wu J; Fink JC
Value Health; 2014; 17(1):51-61. PubMed ID: 24438717
[TBL] [Abstract][Full Text] [Related]
18. Incidence and costs of cardiometabolic conditions in patients with schizophrenia treated with antipsychotic medications.
Jerrell JM; McIntyre RS; Tripathi A
Clin Schizophr Relat Psychoses; 2010 Oct; 4(3):161-8. PubMed ID: 20880826
[TBL] [Abstract][Full Text] [Related]
19. Estimating the Impact of Adherence to and Persistence with Atypical Antipsychotic Therapy on Health Care Costs and Risk of Hospitalization.
Jiang Y; Ni W
Pharmacotherapy; 2015 Sep; 35(9):813-22. PubMed ID: 26406773
[TBL] [Abstract][Full Text] [Related]
20. Prescriber continuity and medication adherence for complex patients.
Hansen RA; Voils CI; Farley JF; Powers BJ; Sanders LL; Sleath B; Maciejewski ML
Ann Pharmacother; 2015 Mar; 49(3):293-302. PubMed ID: 25549627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
